Department of Pharmacology & Chemical Biology at the University of Pittsburgh
Michael T. Lotze, MD
Professor, Surgery and Bioengineering
Pittsburgh, PA 15213

Phone: 412-623-5977


BMSc and MD (Medical Education) from Northwestern University.

Research Areas
Pharmacology of Cell and Organ Systems
Signal Transduction
Photo of Michael T. Lotze, MD

Michael T. Lotze, MD is professor of Surgery and Bioengineering; vice chair of research within the Department of Surgery; assistant vice chancellor in the six schools of the Health Sciences at the University of Pittsburgh; and director of Strategic Partnerships within the University of Pittsburgh Cancer Institute as well as the Catalyst Program within the recently funded Clinical and Translational Research Institute. He has worked in the field of Immunology and clinical medicine for over 35 years and believes that a fundamental understanding of cancer biology and immunology is essential to making progress in oncology research.


He received his MD and BMSc from Northwestern University within the Honors Program in Medical Education. His academic career included surgical training at the University of Rochester as well as fellowships at the MD Anderson Institute and the National Cancer Institute (NCI). He was senior investigator in the Surgery Branch of the NCI from 1982-1990 and founding director and chief of the Division of Surgical Oncology at Pitt from 1990-2000 as well as its training program in an SSO approved surgical oncology program.


Dr. Lotze is the co-inventor on 10 patents in dendritic cell vaccines and antigen discovery and serves as associate editor of the Journal of Immunotherapy. He has over 500 publications which include peer reviewed journals and book chapters. He has also edited several texts including three editions of Current Cancer Therapy [with Joshua Rubin], and Cellular Immunology and the Immunotherapy of Cancer [with Olivera J. Finn].


He developed and edited the 4th Edition of the Cytokine Handbook [2003], the 1st edition of Measuring Immunity [2004], and both editions of Dendritic Cells [1998, 2002], with Dr. Angus Thomson as well as Cytokines and Cancer [2007] with Michael Caligiuri.


The research of Dr. Lotze focuses on the role of necrotic cell death and how it modifies immunity and the biology of inflammation and cancer as well as cellular immunotherapy using cytokines, NK cells, and DCs.



Websit at McGowan Institute for Regenerative Medicine - Michael T. Lotze 

Important Publications
Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, gores GJ; Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trial in hepatoellular carcinoma. J Natl Cancer Inst. 2008 May 21;100(10):698-711. Epub 2008 May 13. Review. PMID: 18477802 [PubMed-indexed for MEDLINE]
Moschos SJ, Mandic M, Kirkwood JM, Storkus WJ, Lotze MT. focus on FOCIS: interleukin 2 treatment associated autoimmunity. Clin Immunol. 2008 May;127(2):123-9. Review. PMID: 18405863 [PubMed - indexed for MEDLINE]
Lotze MT, Nepom GT. A nexus of science and clinical immunology: the Federation of Clinical Immunology Societies and the FOCIS Centers of Excellence. Clin Immunol. 2008 May;127(2):119-20. No abstract available. PMID: 18405861 [PubMed - indexed for MEDLINE]
Vakkila J, Demarco RA, Lotze MT. Coordinate NF-kappaB and STAT1 activation promotes development of myeloid type 1 dendritic cells. Scand J Immunol. 2008 Mar;67(3):260-9. PMID: 18261039 [PubMed - indexed for MEDLINE]

Ostberg T, Wähämaa H, Palmblad K, Ito N, Stridh P, Shoshan M, Lotze MT, Harris HE, Andersson U. Oxaliplatin retains HMGB1 intranuclearly and ameliorates collagen type II-induced arthritis. Arthritis Res Ther. 2008;10(1);R1. Epub 2008 Jan 7 PMID:18179697 [PubMed-indexed for MEDLINE]

Back to Top